查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1787988

全球抗蛇毒血清市場預測（截至 2032 年），按類型、品種、分銷管道、最終用戶和地區分類

Snake Antivenom Market Forecasts to 2032 - Global Analysis By Type (Polyvalent Antivenom and Monovalent Antivenom), Species (Elapids, Viperids, Colubrids and Other Snake Species), Distribution Channel, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球抗蛇毒血清市場預計在 2025 年達到 3.8402 億美元，到 2032 年將達到 6.2886 億美元，預測期內的複合年成長率為 7.3%。

抗蛇毒血清是用於治療毒蛇咬傷的生物衍生性藥物。它們含有透過少量非致命劑量的毒液使宿主動物（通常是馬或羊）免疫而產生的抗體。這些抗體可以中和毒液中的毒素，防止組織和重要器官進一步損害。這些抗體在降低蛇毒中毒的死亡率和併發症發揮重要作用。

根據世界衛生組織 (WHO) 統計，全球整體每年約有 270 萬人被蛇咬傷，導致 81,000 至 138,000 人死亡。

蛇咬傷發生率高

蛇咬傷的高發生率仍然是一個突出因素，據估計每年報告的蛇咬傷病例高達270萬例。持續存在的發病率和死亡率風險，尤其是在熱帶和亞熱帶地區，迫使醫療機構和製造商必須確保抗蛇毒血清的供應。高風險地區人口的成長和氣候變遷導致蛇咬傷事件激增，刺激了全球對有效抗蛇毒血清的需求。因此，公共衛生機構越來越重視意識提升、資源配置以及獲得救命治療的機會，這為市場成長提供了巨大的動力。

製造和分銷成本高

抗蛇毒血清的生產是一個複雜且資源密集的過程，涉及動物免疫、提取和純化，所有這些都需要專門的基礎設施和專業知識。這些因素增加了產品成本，並對蛇咬傷頻繁的中低收入者的負擔能力產生了負面影響。此外，一些國家薄弱的報銷政策和缺乏價格監管，加劇了藥物的可及性挑戰，並限制了抗蛇毒血清治療的普及，尤其是在弱勢群體中。

改進物流和數位工具

供應鏈最佳化、數位追蹤和庫存管理的進步，正在增強抗蛇毒血清向偏遠高風險地區的及時配送。數位平台有助於即時監控存量基準，從而快速應對當地短缺情況，並提高整體配送效率。此外，遠端醫療和醫療資訊系統的實施有助於培訓醫療專業人員，加強事件報告，並快速傳播治療通訊協定，最終改善有效治療的可近性，並擴大市場。

監管障礙和核准延遲

抗蛇毒血清的核准流程通常冗長且各國不一致，導致新產品或改良產品的上市嚴重延誤。這種監管複雜性扼殺了創新，並限制了更安全、更有效的抗蛇毒血清的引入，尤其是在醫療資源匱乏的地區。此外，標準碎片化和協調不力增加了成本，並使全球分銷工作更加複雜。隨著科學進步，監管調整的延遲也可能限制下一代解決方案的快速部署，這對相關人員構成持續挑戰。

COVID-19的影響：

新冠疫情為抗蛇毒血清市場帶來了嚴峻挑戰。供應鏈中斷、旅遊限制導致的就診人數減少以及醫療體系內部工作重點的轉變，導致疫情高峰期抗蛇毒血清需求低於預期。儘管治療延誤和限制導致部分地區蛇咬傷死亡率上升，但全球市場的銷售和產量仍暫時下降。隨著疫情情勢好轉，市場正努力恢復分銷，以滿足疫情後預期的需求復甦。

預測期內，多效價抗蛇毒血清市場預計將佔最大佔有率

多效價蛇毒血清細分多效價預計將在預測期內佔據最大市場佔有率，這得益於其在蛇類種群分佈區域具有廣泛的療效和效用，因為它能夠同時中和多種蛇毒。急診護理中多價抗蛇毒血清的應用日益增多，以及尋求多功能治療方案的臨床醫生的認可，正在增強該細分市場的實力。此外，持續的技術進步和政府對抗蛇毒血清生產日益成長的支持，預計將增強多效價抗蛇毒血清在全球市場的主導地位。

預計預測期內診所部門的複合年成長率最高

預計診所細分市場將在預測期內實現最高成長率，這得益於蛇咬傷管理專科診所的不斷增多，尤其是在蛇咬傷高發的農村和服務匱乏地區。診所提供快速介入和常規抗蛇毒血清，同時減輕了大型醫院的負擔。此外，政府旨在提高農村地區醫療和臨床能力的支持措施進一步提升了成長前景，使診所成為提高治療覆蓋率和擴大市場規模的重要因素。

佔比最大的地區：

預計亞太地區將在預測期內佔據最大市場佔有率，這主要由於抗蛇毒血清的負擔過重，尤其是在印度和東南亞等國家。亞太地區患者人數眾多，加上政府和非政府部門為提高公眾意識、預防和獲取抗蛇毒血清的管道而採取的強力舉措，推動了該地區強勁的需求。此外，本地製造商的投資不斷增加以及醫療基礎設施的改善，也支持了該地區在全球市場的主導地位。

複合年成長率最高的地區：

預計亞太地區在預測期內將呈現最高的複合年成長率，這得益於該地區持續的醫療發展、日益成長的蛇咬治療意識以及在抗蛇毒血清研發和分銷方面的大量投資。擴大農村和服務欠缺地區的醫療保健服務，以及努力縮小治療差距，將在這一預期成長中發揮關鍵作用。此外，政府對國內製造業的大力支持和簡化的監管法規預計將進一步推動該地區的成長。

免費客製化

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球抗蛇毒血清市場（按類型）

  • 多效價蛇毒血清
  • 單價抗毒素

6. 全球抗蛇毒血清市場（依類型）

  • 眼鏡蛇
  • 毒蛇
  • 遊蛇
  • 其他

7. 全球抗蛇毒血清市場（依分銷管道）

  • 直接競標（政府採購）
  • 醫院藥房
  • 零售藥局

8. 全球抗蛇毒血清市場（依最終用戶）

  • 醫院
  • 診所
  • 軍事和偏遠設施
  • 非政府組織和衛生使命

9. 全球抗蛇毒血清市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：主要發展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章：公司簡介

  • BTG International Inc.
  • CSL Limited
  • Bharat Serums and Vaccines Ltd.
  • Instituto Clodomiro Picado（ICP）
  • Serum Institute of India（SII）
  • Inimmune
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Sanofi Genzyme
  • Zydus
  • Daewoong
  • MicroPharm Limited
  • Rare Disease Therapeutics Inc.
  • South African Vaccine Producers（Pty）Ltd.
  • Laboratorios Silanes
Product Code: SMRC30253

According to Stratistics MRC, the Global Snake Antivenom Market is accounted for $384.02 million in 2025 and is expected to reach $628.86 million by 2032 growing at a CAGR of 7.3% during the forecast period. Snake antivenom is a biologically derived therapeutic used to treat venomous snakebites. It contains antibodies developed by immunizing host animals, typically horses or sheep, with small, non-lethal doses of venom. These antibodies neutralize toxins present in the snake venom, preventing further damage to tissues and vital organs. They play a critical role in reducing mortality and complications from envenomation.

According to the World Health Organization (WHO), an estimated 2.7 million cases of snake envenoming occur globally each year, resulting in 81,000 to 138,000 deaths.

Market Dynamics:

Driver:

High incidence of snakebites

The high incidence of snakebites remains a prominent driver, with an estimated 2.7 million cases of snake envenomation reported annually. The persistent risk of morbidity and mortality, especially across tropical and subtropical regions, is compelling healthcare authorities and manufacturers to ensure robust availability of antivenom. A surge in snakebite incidents driven by expanding human populations into high-risk areas and changing climate patterns has expedited global demand for effective antidotes. Consequently, public health institutions are placing increased focus on awareness, resource allocation, and access to life-saving treatments, providing notable impetus to market growth.

Restraint:

High production and distribution costs

Manufacturing antivenom is a complex and resource-intensive process, involving immunization of animals, extraction, and purification, all of which require specialized infrastructure and expertise. These factors contribute to elevated product costs, which adversely affect affordability in low- and middle-income regions where snakebites are frequent. Additionally, inadequate reimbursement policies and a lack of pricing regulation in several countries exacerbate access challenges, thereby limiting the reach of antivenom treatments, especially among vulnerable populations.

Opportunity:

Improving logistics and digital tools

Advances in supply chain optimization, coupled with digital tracking and inventory management, are enhancing the timely distribution of antivenom to remote, high-risk areas. Digital platforms facilitate real-time monitoring of stock levels, enabling swift response to local shortages and improving overall delivery efficiency. Furthermore, the adoption of telemedicine and health information systems supports training for healthcare professionals, bolsters incident reporting, and ensures that treatment protocols are rapidly disseminated, ultimately improving access to effective care and market expansion.

Threat:

Regulatory barriers and approval delays

The antivenom approval process is often prolonged and inconsistent across countries, leading to substantial delays in bringing new or improved products to market. Such regulatory complexities hinder innovation and limit the introduction of safer, more effective antivenoms, particularly in underserved regions. Moreover, fragmented standards and limited harmonization increase costs and complicate global distribution efforts. The slow adaptation of regulations amid evolving scientific advancements may also restrict rapid deployment of next-generation solutions, presenting a continuing challenge for stakeholders.

Covid-19 Impact:

The Covid-19 pandemic imposed significant challenges on the snake antivenom market. Disruptions in supply chains, reduction in healthcare facility visits due to movement restrictions, and shifting priorities within health systems resulted in lower-than-expected demand for antivenom during the peak periods of the pandemic. Although some regions saw an increase in snakebite-related mortality due to delayed or restricted care, the overall global market experienced a temporary decline in sales and production. As pandemic conditions have improved, efforts are underway to restore distribution and address the post-pandemic resurgence in demand.

The polyvalent antivenom segment is expected to be the largest during the forecast period

The polyvalent antivenom segment is expected to account for the largest market share during the forecast period, attributed to the capacity of polyvalent antivenoms to neutralize toxins from multiple snake species simultaneously, providing broad-spectrum efficacy and greater utility in areas with diverse snake populations. Their increased adoption in emergency medical scenarios and favorability among clinicians seeking versatile treatment options reinforce segment strength. Furthermore, ongoing technological advancements and heightened governmental support for antivenom production are anticipated to bolster the dominance of polyvalent antivenoms in the global market landscape.

The clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the clinics segment is predicted to witness the highest growth rate, driven by the growing establishment of specialized clinics dedicated to snakebite management, particularly in rural and underserved regions where snakebites are most prevalent. Clinics offer swift intervention and routine access to antivenom while alleviating patient load from major hospitals. Additionally, supportive government initiatives aimed at rural healthcare and capacity-building in clinical settings further amplify growth prospects, making clinics an essential driver for improvement in treatment coverage and market expansion.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to the region's disproportionately high burden of snake envenomation, especially in countries such as India and Southeast Asian nations. Asia Pacific's substantial patient population, coupled with strong governmental and non-governmental initiatives to enhance awareness, prevention, and access to antivenom, drives robust demand. Additionally, the increased investments by local manufacturers and improvements in healthcare infrastructure further support the region's commanding share in the global market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by the region's continuous healthcare development, rising awareness of snakebite treatment, and significant investments in antivenom research and distribution. Expansion of healthcare delivery to rural and underserved areas, coupled with efforts to reduce treatment gaps, plays a critical role in this anticipated growth. Moreover, strong governmental backing for domestic manufacturing and regulatory streamlining is expected to further propel growth in this region.

Key players in the market

Some of the key players in Snake Antivenom Market include BTG International Inc., CSL Limited, Bharat Serums and Vaccines Ltd., Instituto Clodomiro Picado (ICP), Serum Institute of India (SII), Inimmune, Pfizer, Inc., Merck & Co., Inc., Haffkine Bio-Pharmaceutical Corporation Ltd., Sanofi Genzyme, Zydus, Daewoong, MicroPharm Limited, Rare Disease Therapeutics Inc., South African Vaccine Producers (Pty) Ltd., and Laboratorios Silanes.

Key Developments:

In April 2025, CSL has expanded its antivenom product range, focusing on faster-acting formulations and broader species coverage. This enhances treatment in regions such as South Asia, where snakebites remain critical.

In April 2025, BSV collaborated with the Indian Institute of Science (IISc) to produce test batches of region-specific anti-snake venoms in India, aiming for more effective responses to local venom variability not addressed by the standard polyvalent ASVs.

Types Covered:

  • Polyvalent Antivenom
  • Monovalent Antivenom

Species:

  • Elapids
  • Viperids
  • Colubrids
  • Other Snake Species

Distribution Channels Covered:

  • Direct Tender (Government Procurement)
  • Hospital Pharmacies
  • Retail Pharmacies

End Users Covered:

  • Hospitals
  • Clinics
  • Military & Remote Field Facilities
  • NGOs & Health Missions

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Snake Antivenom Market, By Type

  • 5.1 Introduction
  • 5.2 Polyvalent Antivenom
  • 5.3 Monovalent Antivenom

6 Global Snake Antivenom Market, By Species

  • 6.1 Introduction
  • 6.2 Elapids
  • 6.3 Viperids
  • 6.4 Colubrids
  • 6.5 Other Snake Species

7 Global Snake Antivenom Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Direct Tender (Government Procurement)
  • 7.3 Hospital Pharmacies
  • 7.4 Retail Pharmacies

8 Global Snake Antivenom Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Military & Remote Field Facilities
  • 8.5 NGOs & Health Missions

9 Global Snake Antivenom Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 BTG International Inc.
  • 11.2 CSL Limited
  • 11.3 Bharat Serums and Vaccines Ltd.
  • 11.4 Instituto Clodomiro Picado (ICP)
  • 11.5 Serum Institute of India (SII)
  • 11.6 Inimmune
  • 11.7 Pfizer, Inc.
  • 11.8 Merck & Co., Inc.
  • 11.9 Haffkine Bio-Pharmaceutical Corporation Ltd.
  • 11.10 Sanofi Genzyme
  • 11.11 Zydus
  • 11.12 Daewoong
  • 11.13 MicroPharm Limited
  • 11.14 Rare Disease Therapeutics Inc.
  • 11.15 South African Vaccine Producers (Pty) Ltd.
  • 11.16 Laboratorios Silanes

List of Tables

  • Table 1 Global Snake Antivenom Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Snake Antivenom Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Snake Antivenom Market Outlook, By Polyvalent Antivenom (2024-2032) ($MN)
  • Table 4 Global Snake Antivenom Market Outlook, By Monovalent Antivenom (2024-2032) ($MN)
  • Table 5 Global Snake Antivenom Market Outlook, By Species (2024-2032) ($MN)
  • Table 6 Global Snake Antivenom Market Outlook, By Elapids (2024-2032) ($MN)
  • Table 7 Global Snake Antivenom Market Outlook, By Viperids (2024-2032) ($MN)
  • Table 8 Global Snake Antivenom Market Outlook, By Colubrids (2024-2032) ($MN)
  • Table 9 Global Snake Antivenom Market Outlook, By Other Snake Species (2024-2032) ($MN)
  • Table 10 Global Snake Antivenom Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 11 Global Snake Antivenom Market Outlook, By Direct Tender (Government Procurement) (2024-2032) ($MN)
  • Table 12 Global Snake Antivenom Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 13 Global Snake Antivenom Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 14 Global Snake Antivenom Market Outlook, By End User (2024-2032) ($MN)
  • Table 15 Global Snake Antivenom Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 16 Global Snake Antivenom Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 17 Global Snake Antivenom Market Outlook, By Military & Remote Field Facilities (2024-2032) ($MN)
  • Table 18 Global Snake Antivenom Market Outlook, By NGOs & Health Missions (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.